drugset / Trial / NCT03877952

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

NCT03877952

Phase 1 Completed 6 enrolled Corcept Therapeutics
NaSingle-groupOpen-labelBasic science

Summary

This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of 14C-CORT125281 in healthy participants.

Timeline

Start
2018-09-13
Primary completion
2018-11-01
Completion
2018-11-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Exicorilant Small molecule 360 mg Oral

Indications

No indication recorded.